1. Accuracy of immunological tests on serum and urine for diagnosis of Taenia solium neurocysticercosis: A systematic review.
- Author
-
Van Acker, Lisa, Toribio, Luz, Chachage, Mkunde, Zeng, Hang, Devleesschauwer, Brecht, Garcia, Héctor H., and Gabriël, Sarah
- Subjects
- *
TAENIA solium , *NEGLECTED diseases , *NEUROCYSTICERCOSIS , *DISEASE management , *MIDDLE-income countries - Abstract
Background: Taenia solium neurocysticercosis is a zoonotic neglected tropical disease, for which adequate diagnostic management is paramount, especially in patients with active cysts for whom improved and timely management could prove beneficial. Immunodiagnosis can potentially partially mitigate the necessity for neuroimaging, shortening the diagnostic -and treatment- pathway. An up-to-date review of immunological test performance is however lacking. Methodology/Principal findings: Searches were performed in PubMed, EMBASE, Web of Science, and Scopus (up to January 2024), with included records fitting the review scope, i.e. accuracy evaluation of an antibody-/or antigen-detecting immunological test, using serum or urine of humans confirmed via reference standard (i.e. neuroimaging or surgery/biopsy). Record data was assessed, with classification of descriptive data on cyst localization and stage according to a developed confidence scale, and with selection of tests evaluated on a sufficiently high sample size. A QUADAS-2 risk of bias assessment was performed. After screening, 169 records were included for data collection, with 53 records—corresponding to 123 tests- selected for analysis. Absence of data and large data heterogeneity complicated result interpretation. The lentil lectin-bound glycoprotein enzyme-linked immunoelectrotranfser blot seems to fulfill high accuracy standards regarding detection of parenchymal active multiple cysts; also antigen-detecting tests on serum and urine performed well, additionally in detection of extraparenchymal neurocysticercosis. A novel multi-antigen print immunoassay is highly promising, with sensitivity for detection of extraparenchymal and parenchymal active single and multiple cysts of 100.0%, and specificity of 98.5%. Point-of-care tests showed promising results, however require further evaluation in targeted resource-poor settings. Conclusions/Significance: The review highlights the importance of transparent and unambiguous data reporting. With promising immunological tests in development, the challenge before usage in targeted settings will be to perform large-scale evaluations whilst holding into account both optimized test performance and ease of use. Accessibility to validated tests and feasibility of implementation should also be considered. Author summary: Neurocysticercosis is an important, but neglected disease in many low- and middle-income countries. In resource-poor areas, management of the disease is impeded by lack of availability of, and access to, adequate diagnostic techniques. Immunological tests, performed on serum or urine of affected humans, could be tools of interest in improving the diagnostic pathway. This systematic review provides an overview of immunological tests that have been evaluated so far, and especially focusses on test performance in detection of cysts with specific localization, stage and number. Results on test accuracy proved difficult to retrieve from published records. The comparison of obtained test results was exceedingly challenging due to large heterogeneity. With usable data meticulously selected, several known test formats, such as the LLGP-EITB and the antigen ELISA, showed expected performance results, and some novel test formats, such as the multi-antigen print immunoassay, were highly promising. Also, urine-based tests could provide a non-invasive alternative to serum-based tests. Evaluation of immunological tests in non-clinical settings requires a sufficient sample size for further analysis of data. To improve management of the disease in targeted resource-poor settings, immunological test formats will have to comply with high performance and ease-of-use standards, to optimize chances of future implementation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF